A phase I dose-escalation study of flavopiridol [alvocidib] (NSC 649890) administered as a 30 minute loading dose followed by a 4-hour infusion in patients with B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) following cytoreduction with chemotherapy

Trial Profile

A phase I dose-escalation study of flavopiridol [alvocidib] (NSC 649890) administered as a 30 minute loading dose followed by a 4-hour infusion in patients with B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) following cytoreduction with chemotherapy

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Alvocidib (Primary) ; Allopurinol; Ciprofloxacin; Dexamethasone; Dexamethasone; Pegfilgrastim; Valaciclovir
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top